The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

November 28, 2006 06:30 ET

Medipattern to Customize a Version of B-CAD'TM' for Sonocine, Inc.

TORONTO, ONTARIO--(CCNMatthews - Nov. 28, 2006) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided diagnosis (CAD) software for medical imaging, is very pleased to announce that it will be providing a customized version of B-CAD for SonoCine Inc. an OEM developer of a proprietary whole-breast screening ultrasound system for breast cancer detection using standard ultrasound machines. This customization represents a key element in Medipattern's newly focused sales strategy and reflects the Company's increasing industry profile and growing direct relationships with original equipment manufacturers (OEMs).

SonoCine, Inc. is a new, privately held medical technology company that has developed an innovative, patented, investigational imaging process. Early study data suggest that SonoCine considerably enhances the physician's ability to diagnose breast cancer, using images generated by state-of-the-art medical scanners. Developed by Dr. Kevin Kelly, SonoCine's whole-breast screening process for breast cancer detection and diagnosis transfers sonographic cine loops or video streams to a Windows™-based computer. It optimizes viewing conditions, including review speed, image size, contrast, gamma, and brightness in both two- and three-dimensional formats. In the current clinical study comparing SonoCine and mammography, there was a more than 100% increase in cancers detected when SonoCine was combined with mammography.

"Dr. Kelly's energy and enthusiasm are legendary in breast imaging," said Jeff Collins, President and CEO of Medipattern. "He is a pioneer in breast ultrasound and has worked tirelessly for years to conduct the clinical trial that demonstrates this device's effectiveness. Working with him and SonoCine significantly expands Medipattern's profile in the industry."

"I had been looking to add CAD to SonoCine, and finding B-CAD was the missing link in our technology," said Dr. Kevin Kelly. "I have many years of experience in reading breast ultrasound exams, and Medipattern will allow the easy dissemination of my knowledge and process into a convenient interface. We look forward to working with Medipattern on a detection and diagnosis package that will speed up the reading process and learning curve for radiologists."

David M. Faddis, MD, Oncological Surgeon and Past President of the Medical Staff at Huntington Memorial Hospital, Pasadena, CA, stated, "SonoCine detected two malignant tumours, one in each breast of my patient, B.G., that were missed by the mammogram she'd had only two months earlier. She immediately underwent surgery and today is cancer-free. SonoCine probably saved her life. SonoCine is breakthrough investigational technology for early breast cancer detection."

While complete details of the companies' arrangement are being withheld at this time for competitive reasons, the ultrasound segment of the breast imaging business in North America is currently valued at more than $1 billion, so there is a sizeable potential market for SonoCine with B-CAD.

The SonoCine system can be seen in the North American Imaging booth #3103 at RSNA in Chicago or by visiting the web at www.sonocine.com.

Upcoming Events:

Medipattern will be at the Radiology Society of North America conference, November 26 to November 30, 2006, and plans to demonstrate its software at the Kodak, Confirma, and Cedara booths.

Medipattern's annual general meeting is to be held December 7, 2006 at 10:00 AM EST in the boardroom of WeirFoulds in the Exchange Tower, Suite 1600, 130 King Street West in Toronto. Please contact Robin Sundstrom at 416-368-8770 x223 if you plan to attend.you plan to attend.

About SonoCine, Inc.

SonoCine, Inc is a new, privately held medical technology company with an innovative, patented, investigational imaging process generating high-resolution cine loops that can be viewed on a Windows™-equipped computer. Early study data suggest that SonoCine considerably enhances a physician's ability to evaluate and analyse images generated by medical scanners. At present, the most important use of SonoCine is computer-guided, screening, whole-breast ultrasound for cancer detection. When used with mammography, SonoCine enables earlier detection, and reduces both the chance of undetected breast cancer and the necessity for radical or invasive treatment in women with dense breast tissue.

About The Medipattern Corporation

Medipattern develops computer-aided diagnosis (CAD) software applications for medical imaging. These applications enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and the award-winning B-CAD MRI™. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Please visit the company's website at: www.medipattern.com.

B-CAD™ and B-CAD MRI™ are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information